United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

Zacks2023-05-04

United Therapeutics UTHR first-quarter 2023 earnings of $4.86 per share beat the Zacks Consensus Estimate of $4.35 per share and our model estimate of $3.94 per share. Earnings declined 3% year over ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2332219304?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","is_english":true,"pubTime":"2023-05-04 21:04","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2332219304","market":"us","top_or_hot":-1,"title":"United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss","media":"Zacks","content":"<div>\n<p>United Therapeutics UTHR first-quarter 2023 earnings of $4.86 per share beat the Zacks Consensus Estimate of $4.35 per share and our model estimate of $3.94 per share. Earnings declined 3% year over ...</p>\n\n<a href=\"https://finance.yahoo.com/news/united-therapeutics-uthr-q1-earnings-130401316.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-04 21:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/united-therapeutics-uthr-q1-earnings-130401316.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>United Therapeutics UTHR first-quarter 2023 earnings of $4.86 per share beat the Zacks Consensus Estimate of $4.35 per share and our model estimate of $3.94 per share. Earnings declined 3% year over ...</p>\n\n<a href=\"https://finance.yahoo.com/news/united-therapeutics-uthr-q1-earnings-130401316.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"https://finance.yahoo.com/news/united-therapeutics-uthr-q1-earnings-130401316.html","article_id":"2332219304","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2332219304","pubTimestamp":1683205441,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"United Therapeutics UTHR first-quarter 2023 earnings of $4.86 per share beat the Zacks Consensus Est","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"United Therapeutics(UTHR)第一季度盈利超过预期，销售额低于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1,"JNCE":0.9},"content_text":"United Therapeutics UTHR first-quarter 2023 earnings of $4.86 per share beat the Zacks Consensus Estimate of $4.35 per share and our model estimate of $3.94 per share. Earnings declined 3% year over year.\nRevenues in the reported quarter were $506.9 million, which missed the Zacks Consensus Estimate of $514.0 million. Revenues rose 10% year over year, driven by Tyvaso. The reported revenues, however, beat our model estimate of $497.4 million.\nQuarter in Detail\nUnited Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Remodulin, Tyvaso, Adcirca and Orenitram. It also markets Unituxin for the treatment of pediatric patients with high-risk neuroblastoma.\nTyvaso sales totaled $238.4 million, up 39% year over year, gaining from higher sales volume driven by the launch of Tyvaso dry powder inhalation (DPI) formulation last year in June. Net sales also rose on account of increased product uptake following label expansion of the drug in pulmonary hypertension associated with the interstitial lung disease (PH-ILD) indication in 2021.\nHowever, Tyvaso sales missed the Zacks Consensus Estimate of $259 million.\nThe demand trends of Tyvaso remain strong and the company continues to see new patient growth. However, distributors’ destocking through the first quarter of 2023 due to significant orders of the nebulized formulation in 2022 hurt sales to an extent in the quarter.\nUnited Therapeutics developed the Tyvaso DPI in partnership with MannKind Corporation MNKD. Per an existing commercial supply agreement, MannKind Corporation is responsible for manufacturing and supplying Tyvaso DPI to United Therapeutics.\nUnited Therapeutics is seeing strong demand for Tyvaso DPI but it does not have sufficient inventory to meet the demand. Though partner MannKind is working to increase DPI production capacity, the supply issue may continue through 2023\nShares of United Therapeutics were down 4.5% in response to the mixed results and Tyvaso miss. However, the stock has risen 16.8% in the past year period against the industry’s decline of 7.8%.\nImage Source: Zacks Investment Research\nRemodulin (including Remunity Pump) sales declined 8% year over year to $121.4 million, while Orenitram sales rose 7% year over year, amounting to $88.2 million.\nUnituxin sales reached $49.1million, down 12% year over year. Adcirca sales were $7.3 million, down 26% year over year.\nResearch and development expenses were $82.9 million in the quarter, up 20% year over year. Selling, generaland administrative expenses rose 11% to $87.3 million in the quarter.\nPipeline Update\nUnited Therapeutics is working on expanded indications for Orenitram and Tyvaso. Some phase III studies are ongoing across various forms of PH and pulmonary fibrosis indications.\nKey phase III programs include Tyvaso in patients with various forms of chronic fibrosing interstitial lung disease (TETON studies) and oral ralinepag (PAH — ADVANCE CAPACITY and ADVANCE OUTCOMES studies).\nThe late-stage TETON 1 study in patients with idiopathic pulmonary fibrosis (IPF) is currently enrolling patients at sites located in the United States and Canada. The second phase III study of Tyvaso in IPF patients, TETON 2, which was initiated in October 2022, is being conducted outside of the United States and Canada. If the drug is approved for the IPF indication, management expects Tyvaso sales in IPF to exceed the drug’s sales in the PAH indication. Enrollment is ongoing in the ADVANCE CAPACITY and ADVANCE OUTCOMES studies.\nZacks Rank & Key Pick\nUnited Therapeutics currently carries a Zacks Rank #3 (Hold).\n\nUnited Therapeutics Corporation Price, Consensus and EPS Surprise\n\nUnited Therapeutics Corporation price-consensus-eps-surprise-chart | United Therapeutics Corporation Quote\n\nSome better-ranked stocks in the same sector are Larimar Therapeutics LRMR and Jounce Therapeutics JNCE. While Larimar Therapeutics has a Zacks Rank of 1 (Strong Buy), Jounce Therapeutics has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nLoss estimates for Larimar Therapeutics have narrowed from $2.07 per share to $1.08 per share for 2023 over the past 60 days and from $2.28 per share to $1.15 per share for 2024. Shares of Larimar Therapeutics have risen 15.9% in the past year.\nEarnings of LRMR beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 36.06%. In the last reported quarter, LRMR earnings beat estimates by 73.08%.\nLoss estimates for Jounce Therapeutics’ have narrowed from $2.02 per share to $1.71 per share for 2023 over the past 60 days and from $1.72 per share to $1.03 per share for 2024. Shares of Jounce Therapeutics have declined 63.9% in the past year.\nJNCE delivered an average three-quarter negative earnings surprise of 5.22%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMannKind Corporation (MNKD) : Free Stock Analysis Report\nUnited Therapeutics Corporation (UTHR) : Free Stock Analysis Report\nJounce Therapeutics, Inc. (JNCE) : Free Stock Analysis Report\nLarimar Therapeutics, Inc. (LRMR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2332219304"}